Real-World Use and Acceptance of Biosimilar Monoclonal Antibodies of Rituximab in Oncology Practice in the USA

Figures & data

Table 1. Patient and provider characteristics.

Variables	n (%)
Age (years):
– <40	15 (6.0)
– 40–49	^†
– 50–59	38 (15.3)
– 60–64	28 (11.2)
– ≥65	158 (63.5)
Gender:
– Female	113 (45.4)
– Male	136 (54.6)
Region:
– Midwest	61 (24.5)
– Northeast	15 (6.0)
– South	135 (54.2)
– West	38 (15.3)
Insurance:
– Commercial	44 (17.7)
– Medicare	42 (16.9)
– Medicaid	13 (5.2)
– Other	^†
– Missing	148 (59.4)
Provider type (index):
– Internal medicine	15 (6.0)
– Oncology, hematology	135 (54.2)
– Oncology, medical	57 (22.9)
– Other	22 (8.8)
– Missing	20 (8.0)
Provider region (index):
– Midwest	51 (20.5)
– Northeast	14 (5.6)
– South	147 (59.0)
– West	17 (6.8)
– Missing	20 (8.0)
Diagnosis:
– Non-Hodgkin’s lymphoma	193 (77.5)
– Chronic lymphocytic leukemia	28 (11.2)
– Granulomatosis with polyangiitis	^†
– Microscopic polyangiitis	^†
– Other diagnosis	17 (6.8)

† Counts were ≤10 patients and could not be reported.

Table 2. Treatment pattern for patients with non-Hodgkin’s lymphoma.

Treatment	Treatment pre-rituximab-pvvr, n (%)	Concurrent treatment, n (%)
Pharmacological	120 (62.2)	122 (63.2)
Radiation	^†	NA
Surgery	NA	NA
Pharmacological :
– Chemotherapy	94 (48.7)	122 (63.2)
– Immunotherapy	^†	^†
– Targeted therapy	^†	^†
– Any rituximab	82 (42.5)	NA
– Rituximab (Rituxan^®)	79 (40.9)	NA
– Rituximab-abbs (Truxima^®)	^†	NA
Chemotherapy:
– Dexamethasone	72 (37.3)	99 (51.3)
– Prednisone	51 (26.4)	33 (17.1)
– Cyclophosphamide	27 (14.0)	68 (35.2)
– Vincristine	27 (14.0)	69 (35.8)
– Doxorubicin	26 (13.5)	66 (34.2)
– Bendamustine	19 (9.8)	29 (15.0)
– Etoposide	^†	^†
– Methotrexate	^†	NA
– Carboplatin	^†	^†
– Cisplatin	^†	NA
– Cytarabine	^†	^†
– Gemcitabine	^†	NA
– Ifosfamide	^†	NA
Immunotherapy:
– Polatuzumab vedotin	^†	^†
– Lenalidomide	^†	NA
– Obinutuzumab	^†	NA
Targeted therapy:
– Bortezomib	^†	^†
– Ibrutinib	^†	NA
Combination regimens:
– Rituximab + bendamustine	NA	29 (15.0)
– Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone^‡	NA	64 (33.2)

† Counts were ≤10 patients and could not be reported.

‡ With prednisone: 20 (10.4%); without or missing prednisone: 44 (22.8%).

NA: Not available.

Table 3. Treatment pattern for patients with chronic lymphocytic leukemia.

Treatment	Treatment pre-rituximab-pvvr (n = 22), n (%)	Concurrent treatment (n = 14), n (%)
Pharmacological	22 (78.6)	14 (50.0)
Radiation	NA	NA
Surgery	NA	NA
Pharmacological:
– Chemotherapy	17 (60.7)	14 (50.0)
– Immunotherapy	^†	NA
– Targeted therapy	^†	^†
– Any rituximab	11 (39.3)	NA
– Rituximab (Rituxan^®)	^†	NA
– Rituximab-abbs (Truxima^®)	^†	NA
Chemotherapy:
– Dexamethasone	11 (39.3)	12 (42.9)
– Bendamustine	^†	^†
– Prednisone	^†	^†
– Cyclophosphamide	^†	^†
Immunotherapy:
– Obinutuzumab	^†	NA
Targeted therapy:
– Ibrutinib	^†	^†
Combination regimens:
– Rituximab + bendamustine	NA	^†

† Counts were ≤10 patients and could not be reported.

NA: Not available.

Table 4. Exploratory analysis comparing patient and provider demographics between rituximab-pvvr and rituximab reference medication.

Variables	Rituximab-pvvr (n = 221), n (%)	Rituximab (n = 7100), n (%)	p-value
Age (years):
– <40	12 (5.4)	360 (5.1)	0.056
– 40–49	^†	431 (6.1)
– 50–59	28 (12.7)	1,107 (15.6)
– 60–64	25 (11.3)	923 (13.0)
– 65+	151 (68.3)	4279 (60.3)
Gender:
– Female	95 (43.0)	3074 (43.3)	0.927
– Male	126 (57.0)	4026 (56.7)
– Missing^‡	NA	NA
Region:
– Midwest	50 (22.6)	1852 (26.1)	< 0.001
– Northeast	15 (6.8)	1307 (18.4)
– South	128 (57.9)	2424 (34.1)
– West	28 (12.7)	1484 (20.9)
– Missing^‡	NA	33 (0.5)
Insurance:
– Commercial	40 (18.1)	1861 (26.2)	0.225
– Medicare	39 (17.6)	1467 (20.7)
– Medicaid	^†	686 (9.7)
– Other	^†	132 (1.9)
– Missing^‡	131 (59.3)	2954 (41.6)
Provider type (index):
– Internal medicine	14 (6.3)	774 (10.9)	< 0.001
– Oncology, hematology	129 (58.4)	2579 (36.3)
– Oncology, medical	56 (25.3)	1643 (23.1)
– Other	^†	390 (5.5)
– Missing^‡	19 (8.6)	1714 (24.1)
Provider region (index):
– Midwest	40 (18.1)	1492 (21.0)	< 0.001
– Northeast	14 (6.3)	972 (13.7)
– South	139 (62.9)	1888 (26.6)
– West	^†	1022 (14.4)
– Missing^‡	19 (8.6)	1726 (24.3)

† Counts were ≤10 providers and could not be reported.

‡ Observations with ‘missing’ excluded prior to significance testing.

NA: Not available.